• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

    8.510 +0.960 (+12.72%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 140,315
    Open 7.680
    Bid (Size) 8.400 (4,000)
    Ask (Size) 8.900 (100)
    Prev. Close 7.550
    Today's Range 7.600 - 8.560
    52wk Range 5.328 - 11.52
    Shares Outstanding 19,495,683
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
    The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung... 
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
    Event scheduled for Tuesday, December 2nd at 8:00 AM ET 
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    N/A
    N/A
    1 Month
    +33.4%
    +33.4%
    3 Month
    +41.7%
    +41.7%
    6 Month
    +8.4%
    +8.4%
    1 Year
    +57.9%
    +57.9%

    More News

    Read More
    News headline image
    Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis (NVCT) Q2 Loss Widens 43% ↗
    Via The Motley Fool
    News headline image
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
    Via News Direct
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
    Via News Direct
    News headline image
    Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma to Participate in the 37th Annual Roth Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
    From Market News Alerts
    Via Business Wire
    News headline image
    Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
    From Market News Alerts
    Via Business Wire
    News headline image
    Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Proposed Public Offering of Common Stock
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
    Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
    What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
    Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
    The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
    What is the current price of Nuvectis Pharma, Inc. - Common Stock?
    The current price of Nuvectis Pharma, Inc. - Common Stock is 8.510
    When was Nuvectis Pharma, Inc. - Common Stock last traded?
    The last trade of Nuvectis Pharma, Inc. - Common Stock was at 01/02/26 04:00 PM ET
    What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
    The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 165.91M
    How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
    Nuvectis Pharma, Inc. - Common Stock has 166M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.